| Literature DB >> 32020188 |
Jerilee M K Azhary1, Miyuki Harada1, Chisato Kunitomi1, Akari Kusamoto1, Nozomi Takahashi1, Emi Nose1, Nagisa Oi1, Osamu Wada-Hiraike1, Yoko Urata1, Tetsuya Hirata1, Yasushi Hirota1, Kaori Koga1, Tomoyuki Fujii1, Yutaka Osuga1.
Abstract
Polycystic ovary syndrome (PCOS) is associated with hyperandrogenism, and we previously found that androgens activate endoplasmic reticulum (ER) stress in granulosa cells from patients with PCOS. In addition, recent studies demonstrated the accumulation of advanced glycation end products (AGEs) in granulosa cells from PCOS patients, which contribute to the pathology. Therefore, we hypothesized that androgens upregulate the receptor for AGEs (RAGE) expression in granulosa cells by activating ER stress, thereby increasing the accumulation of AGEs in these cells and contributing to the pathology. In the present study, we show that testosterone increases RAGE expression and AGE accumulation in cultured human granulosa-lutein cells (GLCs), and this is reduced by pretreatment with tauroursodeoxycholic acid (TUDCA), an ER stress inhibitor in clinical use. Knockdown of the transcription factor C/EBP homologous protein (CHOP), an unfolded protein response factor activated by ER stress, inhibits testosterone-induced RAGE expression and AGE accumulation. The expression of RAGE and the accumulation of AGEs are upregulated in granulosa cells from PCOS patients and dehydroepiandrosterone-induced PCOS mice. Administration of the RAGE inhibitor FPS-ZM1 or TUDCA to PCOS mice reduces RAGE expression and AGE accumulation in granulosa cells, improves their estrous cycle, and reduces the number of atretic antral follicles. In summary, our findings indicate that hyperandrogenism in PCOS increases the expression of RAGE and accumulation of AGEs in the ovary by activating ER stress, and that targeting the AGE-RAGE system, either by using a RAGE inhibitor or a clinically available ER stress inhibitor, may represent a novel approach to PCOS therapy. © Endocrine Society 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: advanced glycation end product; androgen; granulosa cell; polycystic ovary syndrome; receptor for advanced glycation end products; unfolded protein response
Mesh:
Substances:
Year: 2020 PMID: 32020188 DOI: 10.1210/endocr/bqaa015
Source DB: PubMed Journal: Endocrinology ISSN: 0013-7227 Impact factor: 4.736